The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.

Onco Targets Ther · 2018 · PMC5927338 · PMID 29731642

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0500

boldest claim

The sentences

a favorable trendp <0.001actually significant

The results suggest a favorable trend in PFS for the patients treated with icotinib+chemotherapy compared to those treated with icotinib alone ( p <0.001, Figure 1A ).

also in 1,335 other papers

did not reach statistical significancep >0.05actually significant

The OS comparison between group B and group C did not reach statistical significance ( p >0.05, Figure 1B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.